

2. Does the study involve use of :				
Drug/Vaccine	Device	Alternative Medicine		
Any Other				
If other, please specify _____				
Not Applicable				
i) Is the test drug/device marketed in India		Yes	No	
Is marketed in other countries:		Yes	No	
Please Specify _____				
If not marketed in India, is DCG(I) permission attached .		Yes	No	
In Additional Documents Chapter On Page no _____				
ii) Is the test drug an Investigational New Drug(IND)?		Yes	No	
If yes, is the Investigator's Brochure which contains data of pre-clinical studies attached.		Yes	No	
In Additional Documents Chapter On Page no _____				
If IND, is attach DCG(I) permission.		Yes	No	
In Additional Documents Chapter On Page no _____				
iii) Does the test drug involve a change in use, dosage, route of administration?		Yes	No	
If yes, is copy of DCG(I) permission attached				
In Additional Documents Chapter On Page no _____				
3. Clinical Study is :				
Phase I	Phase II	Phase III	Phase IV	
4. Subject Selection :				
i) Number of subjects at this centre				
ii) If multicentric,		Total number of subjects	_____	
iii) If multinational ,		Total number of Subject In Indian Centres	_____	
		Total Number of patients in all centres	_____	
iv) Vulnerable subjects: Yes No				
(If yes, circle the correct options)				
Pregnant women	Children	Elderly	Fetus	Illiterate
Handicapped	Seriously/terminally		Mentally challenged	
Economically/socially backward			Any other	
If other, please specify _____				
v) Special group subjects: Yes No (If yes, circle the correct options)				

Employees	Students	Nurses/dependent staff	Any other
If other, please specify _____			
5. Does the study involve use of		Yes	No
i) fetal tissue or abortus		Yes	No
ii) organs or body fluids		Yes	No
iii) recombinant/gene therapy		Yes	No
If yes, is copy of GEAC permission attached In Additional Documents Chapter On Page no ____		Yes	No
iv) ionizing radiation/radioisotopes		Yes	No
If yes, is copy of BARC permission attached In Additional Documents Chapter On Page no ____		Yes	No
v) Infectious/biohazardous specimens		Yes	No
vi) Will pre-existing/stored/left over sample be used?		Yes	No
vii) Will samples be collected for banking/future research		Yes	No
viii) Will any sample collected from patients be sent abroad?		Yes	No
If yes, is copy of DGFT approval /permission attached In Additional Documents Chapter On Page no ____		Yes	No
ix) Is there any collaboration with any foreign lab., clinic or hospital?		Yes	No
If yes, is copy of HMSC approval / permission attached In Additional Documents Chapter On Page no ____		Yes	No
6. Will any advertising be done for recruitment of Subjects? (Posters, flyers, brochures, etc.)		Yes	No
If yes, is a copy for IEC(HR) review In Additional Documents Chapter On Page no ____		Yes	No
7. Data Monitoring			
i) Is there a separate data & safety monitoring board (DSMB)?		Yes	No
ii) Is there a plan for interim analysis of data?		Yes	No
iii) For how long will the trial data be preserved? _____ years			
8. Is there compensation for participation?		Yes	No
If yes, Monetary _____ In kind _____			
Specify amount/type: _____			

9. Is there any arrangement for compensation for trial related injury?	Yes	No
If yes, is copy of HMSC approval / permission attached Additional Documents Chapter On Page no _____		
We hereby declare the information given above to be true and that we do not have any financial or non-financial conflict of interest.		
Name of PI /Designation and Department of PI / Signature of PI		